![Michel Kaczorek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michel Kaczorek
Keine laufenden Positionen mehr
Profil
Michel Kaczorek was involved in the leadership of Kephalios SAS as Chairman and served as a Director at Neurokin SA.
Ehemalige bekannte Positionen von Michel Kaczorek
Unternehmen | Position | Ende |
---|---|---|
Neurokin SA
![]() Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Direktor/Vorstandsmitglied | 11.03.2014 |
Kephalios SAS
![]() Kephalios SAS Medical SpecialtiesHealth Technology Kephalios SAS develops and designs medical equipment including mitral ring for minimally invasive and reversible correction of residual mitral regurgitation. The company was founded in April 2011 and is headquartered in Paris, France. | Vorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Neurokin SA
![]() Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
Kephalios SAS
![]() Kephalios SAS Medical SpecialtiesHealth Technology Kephalios SAS develops and designs medical equipment including mitral ring for minimally invasive and reversible correction of residual mitral regurgitation. The company was founded in April 2011 and is headquartered in Paris, France. | Health Technology |